181 related articles for article (PubMed ID: 23033227)
1. Performance of compliance and persistence measures in predicting clinical and economic outcomes using administrative data from German sickness funds.
Frey S; Stargardt T
Pharmacotherapy; 2012 Oct; 32(10):880-9. PubMed ID: 23033227
[TBL] [Abstract][Full Text] [Related]
2. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients.
Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC
Med Care; 2008 Nov; 46(11):1125-33. PubMed ID: 18953222
[TBL] [Abstract][Full Text] [Related]
3. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study.
Ward A; Ishak K; Proskorovsky I; Caro J
Clin Ther; 2006 Nov; 28(11):1912-21. PubMed ID: 17213012
[TBL] [Abstract][Full Text] [Related]
4. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
Jiang Y; Ni W
Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany.
Stargardt T; Edel MA; Ebert A; Busse R; Juckel G; Gericke CA
J Clin Psychopharmacol; 2012 Oct; 32(5):602-7. PubMed ID: 22926592
[TBL] [Abstract][Full Text] [Related]
7. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia.
Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC
Value Health; 2009 Sep; 12(6):989-95. PubMed ID: 19402852
[TBL] [Abstract][Full Text] [Related]
8. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data.
Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC
Curr Med Res Opin; 2009 Sep; 25(9):2303-10. PubMed ID: 19635045
[TBL] [Abstract][Full Text] [Related]
9. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
10. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
Sun SX; Liu GG; Christensen DB; Fu AZ
Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
[TBL] [Abstract][Full Text] [Related]
11. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
12. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
13. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
Offord S; Lin J; Mirski D; Wong B
Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
[TBL] [Abstract][Full Text] [Related]
14. Association of refill adherence and health care use among adults with hypertension in an urban health care system.
Stroupe KT; Teal EY; Tu W; Weiner M; Murray MD
Pharmacotherapy; 2006 Jun; 26(6):779-89. PubMed ID: 16716131
[TBL] [Abstract][Full Text] [Related]
15. Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia.
Lang K; Federico V; Muser E; Menzin J; Menzin J
J Med Econ; 2013 Aug; 16(8):997-1006. PubMed ID: 23777223
[TBL] [Abstract][Full Text] [Related]
16. Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients' compliance by using computerised pharmacy data.
Rijcken CA; Tobi H; Vergouwen AC; de Jong-van den Berg LT
Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):365-70. PubMed ID: 15170765
[TBL] [Abstract][Full Text] [Related]
17. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
Marcus SC; Olfson M
Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
Ren XS; Crivera C; Sikirica M; Dirani R; Qian S; Kazis LE
J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic, pharmacy-based, and self-reported health measures in risk equalization models.
Stam PJ; van Vliet RC; van de Ven WP
Med Care; 2010 May; 48(5):448-57. PubMed ID: 20393368
[TBL] [Abstract][Full Text] [Related]
20. Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims.
McHorney CA; Victor Spain C; Alexander CM; Simmons J
Clin Ther; 2009 Nov; 31(11):2584-607. PubMed ID: 20110004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
